About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Predicting Effective Therapy in Pancreatic Cancer

NCT03033927·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Memorial Sloan Kettering Cancer Center

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
ECOG performance status 0-2.
A minimum age of 18 years old.

You may not be if

Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
Known to be HIV positive on antiretroviral therapy
Prior organ allograft
Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

The record

StatusActive not recruiting

PhaseNo phase

Taking part74

StartedJan 2017

UpdatedApr 27, 2026

Conditions

Pancreatic Cancer Pancreatic Adenocarcinoma

Where4

Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States
Memorial Sloan Kettering Westchester
Harrison, New York, United States

Clareo Health | Predicting Effective Therapy in Pancreatic Cancer